Presented at Genetics-inspired Therapeutics for PH by Khodr Tello, Justus-Liebig-Universität Gießen

The SPHInX study is the first-ever randomized controlled trial (RCT) seeking to inform an area of equipoise regarding the efficacy of oral anticoagulation as adjunct therapy in systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH).

Presented at Genetics-inspired Therapeutics for PH by Ardeschir Ghofrani, Justus-Liebig-Universität Gießen

In this study, we compared the clinical efficacy and safety of various Yiqi Chinese medicine injections in chronic pulmonary heart disease (CPHD) through pairwise meta-analyses and indirect comparisons within a systematic review. 

Presented at Genetics-inspired Therapeutics for PH by Wei Li, University Of Cambridge

Presented at Genetics-inspired Therapeutics for PH by Marie-Jose Goumans, Leiden University

Presented at Genetics-inspired Therapeutics for PH by Lars Harbaum, Universitätsklinikum Hamburg-Eppendorf

Presented at Genetics-inspired Therapeutics for PH by Richard Trembath, King's College London

A001 Targeting ZIP12 to Modulate Intracellular Zinc and Vascular Dysfunction in Pulmonary Arterial Hypertension, A002 Role of The Protein Ttk in the Vascular Remodeling Processes in Pulmonary Artery Hyerpenstion and more.

Placental Abnormalities of Malperfusion, Inflammation, and Meconium are Associated With Persistent Pulmonary Hypertension of the Newborn, Pulmonary Hypertension-Targeted Therapies in Adult and Pediatric Patients Supported With Ventricular Assist Devices: A Systematic Review and more.